restarting tirzepatide after a month Month: Safe Resumption Guide After a 3 month break
Description
The FDA resolved the semaglutide shortage in February 2025, but 503A compounding for individual patients continues under the Federal Food, Drug, and Cosmetic Act when a prescriber documents that an FDA-approved product isnt suitable for the patients clinical needs
For patients with TIIDM who do not respond well to sulfonylureas, continuous intravenous infusion of GLP-1 significantly lowers blood glucose levels
Extend fasting intervals, use rapid-sequence induction when indicated, and consider preoperative gastric emptying assessment in high-risk patients
Certain medical conditions or medications may make Wegovy inappropriate for you
British Columbia, Alberta, Ontario, and Quebec each maintain separate formularies and coverage criteria for obesity medications
New rules changed what pharmacies can and cannot produce
